Company profile: NeuroSigma
1.1 - Company Overview
Company description
- Provider of trigeminal nerve stimulation (TNS) medical devices and therapies for neurologic and psychiatric disorders. The company commercializes its TNS technology with a pipeline targeting epilepsy, depression, ADHD, and PTSD. Products include the Monarch eTNS System, a non-drug treatment device for pediatric ADHD used during sleep under caregiver supervision.
Products and services
- Trigeminal Nerve Stimulation (TNS) Technology: Unique platform that stimulates the trigeminal nerve for neurologic and psychiatric disorders, supporting treatments for epilepsy, depression, ADHD, and PTSD
- Monarch eTNS System: Non-drug device for pediatric ADHD, used during sleep under caregiver supervision, delivering trigeminal nerve stimulation as a nighttime therapy
- TNS Treatment Pipeline: Indication-targeted portfolio expanding trigeminal nerve stimulation therapies for epilepsy, depression, ADHD, and PTSD, with a focus on commercialization for neurologic and psychiatric disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeuroSigma
Annovis Bio
HQ: United States
Website
- Description: Provider of treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders, including: Buntanetap, an oral small molecule inhibiting multiple neurotoxic proteins; ANVS405, an IV formulation for acute neurodegeneration like TBI and stroke; and ANVS301, a Phase 1 compound aiming to increase cognitive capabilities in later-stage Alzheimer’s and dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annovis Bio company profile →
Inscopix
HQ: United States
Website
- Description: Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inscopix company profile →
NeuroReality
HQ: The Netherlands
Website
- Description: Provider of VR-based cognitive rehabilitation and brain training solutions using neuroscience and gamification. Offers Koji's Quest, a patient-centric SaaS VR game for recovery from brain injuries, connecting clinicians and patients to improve outcomes and enable superior care. Organizes clinical trials to evaluate effectiveness and prepares Koji's Quest for individual self-training via the Oculus Quest store.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroReality company profile →
XW Pharma
HQ: United States
Website
- Description: Provider of neuroscience biotech R&D focused on sleep, neuropsychiatric, and neglected CNS illnesses. Pipeline includes XWL-008, a proprietary narcolepsy compound preparing for late-stage phase 3; XW10172, a patented once-nightly conjugate of the GABAB agonist oxybate for sleep disorders in patients with neurodegenerative diseases; and XW10508, an oral, once-daily NMDA antagonist/AMPA activator for treatment-resistant depression and chronic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XW Pharma company profile →
SwanBio Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy focused on genetically defined therapies for neurological disorders. Offerings include SBT101, a candidate for adrenomyeloneuropathy targeting ABCD1 via AAV9; pipeline development in spinal cord-related indications; clinical trials, including a Phase 1/2 study of SBT101 and natural history studies of AMN; and patient and family resources, including trial information and compassionate use policies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SwanBio Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeuroSigma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeuroSigma
2.2 - Growth funds investing in similar companies to NeuroSigma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeuroSigma
4.2 - Public trading comparable groups for NeuroSigma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →